All filters
Abstracts
K156N integrase substitution in combination with 3’PPT resistance mutations against dolutegravir
R. Gruters
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Long-term Efficacy, Safety, and Durability of Ibalizumab-based Regimens in Subgroup of TMB- 202 Participants
H. Jullien
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Residual HIV-1 RNA in 4d on/3d off (ANRS 170 QUATUOR) through W96
S. Lambert
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Switch to ART with BIC/FTC/TAF achieves virological control in patients with low level viremia
I. Santos
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Implementation of HCV- infection treatment programm with DAA in armenia among HIV- infected patients in COVID-19 era
N. Sargsyants
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Impacts of Differentiated Service Delivery Model (DSDM) on Adherence (ADH) to clinical appointment Among Children and Adolescent Living with HIV (CALHIV) attending at Mbeya Center of Excellence (COE), Baylor-Tanzania
E. Mgeyi
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
HIV and SARS-CoV-2: the interplay of two wicked problems
A. Vandamme
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Eu HIV & Hep Abstracts 2022_56
L. Ramirez
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Prevalence and viral load suppression rate among children and adolescents with dual infections (any two of HIV, HBV, and HCV) in Nnewi, Nigeria
S. Kalu
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Proviral DNA for detection of HIV-1 subtype A drug resistance mutations
D. Turner
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Combined COVID-19 vaccination and hepatitis C virus screening intervention for high-risk populations at a centre for addiction services in Barcelona, Spain
J. Lazarus
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Combined COVID-19 vaccination and hepatitis C virus and HIV screening intervention for high- risk populations at a mobile testing unit in Madrid, Spain
J. Lazarus
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Community perspectives on self- testing for HIV and HCV in the WHO European region
S. North
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Viral load suppression after three-year Ibalizumab treatment in a multidrug-resistant HIV-1- infected woman: Clinical experience.
I. Santos
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
CASE - HIV+ End-Stage Renal Disease Patient with Immunosuppressive Drug-Drug Interactions Received Successful Transplantation after Ibalizumab Suppressed Switch
S. Sharma
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Clinical course of AIDS with COVID-19 coinfection with prolonged SARS CoV-2 replication despite remdesivir/molnupiravir treatment.
B. Aksak-Wąs
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
A Case of IRIS Syphilis Due to Prozone Effect
Y. Rahman
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Concentration-QTcF modelling and drug-drug interaction of Bedaquiline, Pretomanid and Clofazimine in TB patients.
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021
Abstracts
Incidence and determinants of linezolid toxicity in patients with drug-resistant tuberculosis in a high HIV prevalence setting
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021
Abstracts
A model-guided weight-banded dosing strategy for once daily delamanid in children
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021
Abstracts
A model-based analysis of bedaquiline-related QTcF prolongation in the PROBeX study
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021
Abstracts
A Population Pharmacokinetic Model of Linezolid enabling Model-Informed Precision Dosing in Resistant Tuberculosis Patients
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021
Abstracts
Cerebrospinal Fluid Concentrations of New and Repurposed Drugs among Patients with Tuberculosis Meningitis
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021
Abstracts
Evaluating the effect of clofazimine against Mycobacterium tuberculosis
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021